MiNK Therapeutics will present Phase 2 study data on agenT-797 for refractory gastric cancer at ASCO GI 2025.
Quiver AI Summary
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune diseases, announced it will present a poster at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 23-25, 2025, in San Francisco. The presentation will cover a Phase 2 study of its product agenT-797 combined with Agenus' botensilimab and balstilimab for patients with refractory gastric cancer. The abstract, titled "A Phase II study of agenT-797, botensilimab, and balstilimab in patients with advanced, refractory gastroesophageal adenocarcinoma," will be presented by Dr. Samuel Cytryn. Complete abstracts will be published on January 21, 2025, and materials from the conference will be available on MiNK's website thereafter. The company is headquartered in New York and is advancing a pipeline of iNKT therapies while emphasizing the potential risks associated with forward-looking statements in their communications.
Potential Positives
- Announcement of a poster presentation at the prestigious ASCO GI Symposium, showcasing research on a promising Phase 2 study for refractory gastric cancer.
- Collaboration with Agenus to present innovative therapies combining agenT-797 with botensilimab and balstilimab, highlighting synergistic treatments in oncology.
- Opportunity to enhance visibility and credibility within the oncology community through engagement in a major scientific conference.
Potential Negatives
- The press release emphasizes the company's reliance on forward-looking statements, highlighting the inherent risks and uncertainties associated with their clinical study outcomes, which may create apprehension among investors.
- Details on the ongoing Phase 2 study were not fully disclosed, leaving critical information about efficacy and potential challenges unaddressed, which may lead to concerns regarding transparency.
- The announcement of a presentation at an upcoming symposium suggests that the company is still in the early stages of research, potentially indicating delayed commercialization timelines for their therapies.
FAQ
What is the significance of MiNK Therapeutics' presentation at ASCO GI 2025?
MiNK Therapeutics will present a Phase 2 study of agenT-797 for treating refractory gastric cancer.
When and where will the ASCO GI Symposium take place?
The ASCO GI Symposium will be held from January 23-25, 2025, in San Francisco, California.
Who is the presenting author for the MiNK Therapeutics study?
Dr. Samuel Cytryn is the presenting author for the Phase 2 study of agenT-797.
What is the focus of MiNK Therapeutics?
MiNK Therapeutics focuses on developing allogeneic invariant natural killer T-cell therapies for cancer and immune-mediated diseases.
How can I access data presented at the ASCO GI Meeting?
Data from the ASCO GI Meeting will be available in the publications section of the MiNK website after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INKT Hedge Fund Activity
We have seen 9 institutional investors add shares of $INKT stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 29,831 shares (-100.0%) from their portfolio in Q2 2024
- RENAISSANCE TECHNOLOGIES LLC removed 21,154 shares (-16.5%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 20,809 shares (-100.0%) from their portfolio in Q2 2024
- CAPTRUST FINANCIAL ADVISORS removed 20,407 shares (-57.1%) from their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC removed 17,561 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 13,121 shares (-100.0%) from their portfolio in Q3 2024
- TWO SIGMA SECURITIES, LLC added 11,937 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium that will take place on January 23-25, 2025, in San Francisco, California. The poster presentation will highlight the ongoing Phase 2 study of agenT-797 in combination with Agenus’ botensilimab/balstilimab in patients with refractory gastric cancer.
Presentation Details
Abstract Title:
A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
Abstract Number:
TPS515
Presenting Author:
Dr. Samuel Cytryn
Session:
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Session Date and Time:
1/23/2025, 11:30 AM-1:00 PM
Complete abstracts will be released at 5:00 PM ET on January 21 st , 2025. Data presented at the conference will be available to view in the publications section of the MiNK website ( https://minktherapeutics.com/publications/ ) following the ASCO GI Meeting.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
[email protected]
Media Contact
781-674-4428
[email protected]
